^
Association details:
| Biomarker: | HER-2 S310F + HER-2 amplification |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Enhertu (fam-trastuzumab deruxtecan-nxki) (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Response to Trastuzumab and Lapatinib in a Metastatic Colorectal Cancer Harboring HER2 Amplification and HER2 S310F Mutation
Published date:
06/30/2021
Excerpt:
This report describes a patient with metastatic CRC with concurrent HER2 amplification and a HER2 S310F mutation...Upon disease progression, treatment with the antibody-drug conjugate trastuzumab-deruxtecan resulted in a short-lived response.
DOI:
10.6004/jnccn.2021.7023
